share_log

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Benzinga Real-time News ·  May 5, 2022 20:19

 

Gainers

  • Intercept Pharmaceuticals (NASDAQ:ICPT) stock increased by 41.2% to $22.86 during Thursday's pre-market session. The market value of their outstanding shares is at $678.8 million.
  • Frequency Therapeutics (NASDAQ:FREQ) shares increased by 9.23% to $1.42. The market value of their outstanding shares is at $49.6 million. The company's, Q1 earnings came out yesterday.
  • GT Biopharma (NASDAQ:GTBP) shares rose 8.9% to $2.08. The market value of their outstanding shares is at $66.8 million.
  • Aeglea BioTherapeutics (NASDAQ:AGLE) shares increased by 8.32% to $1.69. The market value of their outstanding shares is at $83.5 million.
  • VYNE Therapeutics (NASDAQ:VYNE) shares increased by 8.05% to $0.48. The market value of their outstanding shares is at $27.6 million.
  • Marinus Pharma (NASDAQ:MRNS) stock moved upwards by 7.66% to $6.6. The company's market cap stands at $244.3 million.

Losers

  • AIkido Pharma (NASDAQ:AIKI) stock decreased by 13.9% to $0.4 during Thursday's pre-market session. The market value of their outstanding shares is at $35.5 million.
  • Kintara Therapeutics (NASDAQ:KTRA) shares declined by 10.85% to $0.24. The company's market cap stands at $15.7 million.
  • Aclarion (NASDAQ:ACON) shares decreased by 10.22% to $2.11. The market value of their outstanding shares is at $16.5 million.
  • Tempest Therapeutics (NASDAQ:TPST) stock decreased by 10.11% to $3.38. The company's market cap stands at $24.2 million.
  • Reshape Lifesciences (NASDAQ:RSLS) shares declined by 10.08% to $0.75. The market value of their outstanding shares is at $2.6 million.
  • Sonoma Pharmaceuticals (NASDAQ:SNOA) stock fell 8.22% to $3.13. The company's market cap stands at $9.6 million. See Also:

This article was generated by Benzinga's automated content engine and reviewed by an editor.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment